[ Diabetes Type 1 ]

Which Diabetes Drug Is Best?

Up to one-third of patients with heart disease have diabetes. “There are very few things experts agree on, but this is one of them,” said Dr. A new study published by Dr. There are no data as to the best time start oral therapy; instead, clinicians should take into account other complicating factors including life expectancy, microvascular and macrovascular complications, risk for adverse events related to glucose control, and patient preference, they wrote. And people with kidney disease generally shouldn’t take it, he said. The disease, which is often linked to obesity, causes blood sugar levels to be chronically high. Long-term outcome studies are awaited to see if they have cardiovascular advantages in any particular group of patients.

“So what we know is that currently, there is no good evidence that one drug can improve life expectancy better than another — either when they are used as the only drug for treatment, or when added to metformin,” said Palmer. This on its own is a major factor when considering the “lifestyle medicine” model, and though it was referred to in the research, there should be greater investigation on how much of a person’s lifestyle choices are actually choices they make versus the conditions they live in or the culture they have been brought up in. Qaseem and colleagues noted that low-quality or insufficient evidence made it difficult to draw conclusions about the comparative effectiveness of medications on all-cause and cardiovascular mortality, cardiovascular and cerebrovascular morbidity, and microvascular outcomes. Other trials looked at newer, more expensive classes, including thiazolidinediones such as pioglitazone (Actos) and rosiglitazone (Avandia); and DPP inhibitors, such as sitagliptin (Januvia) and saxagliptin (Onglyza). That’s important, he explained, because the U.S. We will continue to keep the majority of our content free of charge. So older medications never went through that process.

Plus, Pantalone said, there is evidence from recent trials that two newer diabetes drugs can, in fact, curb the risk of death from heart disease or stroke. Those drugs are an injectable medication called liraglutide (Victoza) and an oral medication called empagliflozin (Jardiance).

Tags: , ,
[ Diabetes Type 2 ]

Which Diabetes Drug Is Best?

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than most new and more expensive classes of medication used to control the chronic disease. 28, 2014 (HealthDay News) — People newly diagnosed with type 2 diabetes who are initially given the drug metformin are less likely to eventually need other drugs to control their blood sugar, a new study suggests. 8 at www.annals.org, Francesco Zaccardi, MD and colleagues at Leicester General Hospital, Leicester, UK summarize the benefits and harms possible with these drugs. Side effects are also listed in the information that comes with your medicine. More than 15 million Americans have type 2 diabetes. According to the researchers, although diabetes patients with uncontrolled blood sugar are at risk for dying from a heart attack or stroke, it hasn’t been clear whether one diabetes drug is better than another in preventing these deaths. When added to metformin, diabetes drugs were associated with similar HbA1c levels, whereas sodium-glucose cotransporter-2 (SGLT-2) inhibitors offered the lowest odds of hypoglycemia.

Type 2 diabetes is a disease of lifestyle: nearly every risk factor for type 2 diabetes involves choices people make and can change: being overweight, lack of exercise, high cholesterol, high blood pressure, impaired glucose tolerance. Supposedly causes fewer/ less unpleasant side effects than competitors; much-discussed among patients. Suetonia Palmer told HealthDay. The studies included six classes of medication: metformin (Glucophage, Fortamet and others); second-generation sulfonylureas (Amaryl, Glucotrol and others); thiazolidinediones (Avandia and Actos); meglitinides (Starlix and Prandin); dipeptidyl peptidase-4 (DPP-4) inhibitors (Januvia and Onglynza); and glucagon-like petide-1 (GLP-1) receptor agonists (Byetta and Victoza). When people have insulin resistance, too much sugar is left in the blood instead of being used. “These findings are consistent with American Diabetes Association recommendations for using metformin monotherapy as initial treatment for patients with type 2 diabetes and selection of additional therapies based on patient-specific considerations,” the authors write. Medicine is one of the many tools your doctor has to treat a health problem.

In the study, Bolen and her colleagues reviewed the scientific evidence from 216 previous studies and compared each drug for its clinical effectiveness, risks and costs. “Metformin, in the absence of contraindications or intolerability, should be the first-line agent to treat patients with type 2 diabetes,” he told HealthDay.

Tags: , ,
[ Diabetes Solutions ]

Which Diabetes Drug Is Best?

TUESDAY, July 19, 2016 (HealthDay News) — No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds. “There are very few things experts agree on, but this is one of them,” said Dr. Today, insulin is still a must for people with type 1, but there are almost a dozen classes of medications for those with type 2 diabetes. Metformin can cause upset stomach and diarrhea, so some patients are unable to stick with it day to day, explained Pantalone, who wasn’t involved in the study. And people with kidney disease generally shouldn’t take it, he said. Elevated levels of blood glucose can cause multiple problems if untreated. However, there are many people with undiagnosed type 2 diabetes so the true number could be considerably higher.

“So what we know is that currently, there is no good evidence that one drug can improve life expectancy better than another — either when they are used as the only drug for treatment, or when added to metformin,” said Palmer. She’s an associate professor in the Department of Medicine at the University of Otago, in New Zealand. This class of drugs stimulates the pancreas to make more insulin, but it also causes weight gain and increases the risk for heart attacks. Other trials looked at newer, more expensive classes, including thiazolidinediones such as pioglitazone (Actos) and rosiglitazone (Avandia); and DPP inhibitors, such as sitagliptin (Januvia) and saxagliptin (Onglyza). Just shy of half of the studies made no mention of race or ethnicity. “From 2004 to 2013, none of the 30 new diabetes drugs that came on the market were proven to improve key outcomes, such as reducing heart attacks or strokes, blindness, or other complications of the disease.”  In other words, Diabetes drugs are much like STATINS. So older medications never went through that process.

Plus, Pantalone said, there is evidence from recent trials that two newer diabetes drugs can, in fact, curb the risk of death from heart disease or stroke. Those drugs are an injectable medication called liraglutide (Victoza) and an oral medication called empagliflozin (Jardiance).

Tags: , ,
[ Diabetes Solutions ]

Which Diabetes Drug Is Best?

A new study has found no clear survival benefits or significant differences among type 2 diabetes patients taking any of nine available antidiabetic drugs (single or in combination) and their all-cause and cardiovascular mortality. Obese and diabetic premenopausal women are most at risk – even more than men of the same age who have similar health issues. The documents were published ahead of a June 28 meeting of outside advisors who will discuss the drug, Jardiance, and recommend whether the label should include a claim that it cuts the risk of heart problems in patients at high risk. The delay, while short, means Novo Nordisk ($NVO) now has a lead in the race to bring an insulin-GLP-1 agonist combination product to market in the U.S. The medication works by blocking the enzyme dipeptidyl peptidase-4, or DPP-4. Poxel raised some of the money from new U.S.-based institutional investors, with another tranche coming from a mix of existing backers from both sides of the Atlantic. However, both risperidone and aripiprazole commonly produce significant weight gain – a worrisome side effect given obesity’s many associated health risks.

Victoza, which is an injectable medication, by the way, belongs to a class of drugs known as GLP-1, while Jardiance is in the SGLT-2 class. “I suspect that [this] trial is not the final word on the issue,” said Dr. The medications included older standbys such as metformin, insulin, and sulfonylureas such as glipizide (Glucotrol) and glimepiride (Amaryl). The antidiabetic drugs involved in the study were basal insulin, metformin, thiazolidinediones, sulfonylureas, sodium-glucose linked transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, meglitinides, α-glucosidase inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The study, “Dipeptidyl Peptidase-4 Inhibition with Linagliptin Prevents Western Diet-induced Vascular Abnormalities in Female Mice,” recently was published in Cardiovascular Diabetology. Food and Drug Administration has only required diabetes drugs to undergo cardiovascular safety testing since 2008. As the additional information represents a major amendment to the NDA, the FDA has pushed back the PDUFA date by three months, meaning it should now make a decision on Novo’s IDegLira before IGlarLixi.

Plus, Pantalone said, there is evidence from recent trials that two newer diabetes drugs can, in fact, curb the risk of death from heart disease or stroke. Poxel is also looking to secure an Asian commercial partner. The researchers saw no changes in obesity-associated metabolic measures such as insulin sensitivity and cholesterol. healthfinder.gov does not endorse opinions, products, or services that may appear in news stories. It’s possible that patients in this study were too sick to benefit from Victoza, Apovian said.

Tags: , ,